Clovis Oncology's (NASDAQ:CLVS) lucitanib has experts optimistic on Phase II breast cancer results given previously demonstrated response rates and a manageable safety profile.
While hypertension was noteworthy, physicians said it is largely manageable, making lucitanib an attractive candidate for targeted therapy.
Evaluating lucitanib's response may be difficult given the growing number of hormone positive breast cancer therapies, experts agreed. The link between fibroblastic growth factor receptor (FGFR) expression and patient response is not yet known, but the Phase II trial is expected to shine a light on this since it recruits patients irrespective of their FGFR1 expression status, they said.
Lucitanib inhibits the tyrosine kinase (TK) activity of FGFR1-3, vascular endothelial growth factors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR α/β).
Data from the Phase II (NCT02202746) 201 patient trial is expected mid-2016, according to analyst reports, with a likely update at the American Society of Clinical Oncology (ASCO) 2016.